Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Rituximab in Treatment-Naive Waldenström's Macroglobulinemia
NCT05099471Phase 2Recruiting
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of venetoclax in Waldenstrom macroglobulinemia (WM) (2 arms). Primary endpoint: Rate of Complete Response / Very Good Partial Response at 12 months. Started Mar 2025; status: recruiting.
02
Drugs
venetoclax
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05099471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099471.